[ad_1]
The Japanese government approved the Kyoto University project to request a clinical trial of Parkinson's disease using allogeneic stem cells (iPS), the Nikkei newspaper reported on June 30.
According to the newspaper, Kyoto University will receive government approval, publish detailed details in a short time and will launch a clinical trial in which cells made of iPS are transplanted in patients with Parkinson's disease.
This is the third time in the world that Parkinson's disease is the first in the world to be approved for cell transplantation in the human body with the help of iPS
Professor Takahashi Jun from Kyoto University
Parkinson's disease is a disease caused by a decrease in nerve cells that secrete dopamine, a neurotransmitter in the brain.
I have symptoms such as tremor or muscle stiffness.
Clinical trials use iPS, which is manufactured by the Kyoto University Research Institute for iPS cells, as a cell of a healthy person, to prevent the decline of nerve cells.
The research team expects that some of the transplanted cells will install in the brain and improve the symptoms, resulting in higher effects on the drugs.
If successful, Dai Nippon Sumitomo Pharmaceutical will continue to develop and market it.
Professor Takahashi and his colleagues found that cells that had been transplanted into monkeys did not become tumors for two years. (19659002) [email protected]
[ad_2]
Source link
